• What is DDR2?
  • DDR2 in Lung Cancer
  • Clinical Trials


DDR2 (discoidin death receptor 2) is a member of the DDR family of receptor tyrosine kinases that are stimulated by collagen rather than peptide growth factors (Figure 1). Downstream signaling in cancer cells is poorly understood but may be via SRC and STAT signaling pathways. Similar to integrin receptors, DDR2 may play a role in modulating cellular interactions with the extracellular matrix.

DDR2 mutations have been found at low frequency in a number of cancers, including renal cell carcinoma, glioblastoma multiforme, endometrial cancer, colorectal cancer (COSMIC). The highest reported frequency is in squamous cell carcinoma of the lung (Hammerman et al. 2011).


Figure 1.
Schematic of DDR2 signaling pathway. Binding of collagen to DDR2 results in activation of downstream signaling pathways. The letter "K" within the schema denotes the tyrosine kinase domain.

Related Pathways

Contributors: Paul K. Paik, M.D.

Suggested Citation: Paik, P. 2015. DDR2. My Cancer Genome https://www.padiracinnovation.org/content/disease/lung-cancer/ddr2/?tab=0 (Updated December 7).

Last Updated: December 7, 2015


DDR2 mutations have been found in 2.5–3.8% of squamous cell carcinomas of the lung and in 4% of lung tumors with adenocarcinoma histology (COSMICHammerman et al. 2011). No hotspots have been identified, with mutations spanning both the kinase and discoidin domains (the latter of which forms part of the extracellular region that binds to collagen; Ichikawa et al. 2007). Neither overexpression of DDR2 nor copy number alterations of the DDR2 locus (1q23) has been reported.


While there are limited data on the clinical characteristics of patients harboring DDR2 mutations, no significant association with sex, age, or smoking status has been found.​​​


Contributors: Paul K. Paik, M.D.

Suggested Citation: Paik, P. 2015. DDR2 in NSCLC. My Cancer Genome https://www.padiracinnovation.org/content/disease/lung-cancer/ddr2/ (Updated June 18).

Last Updated: June 18, 2015

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.padiracinnovation.org to check it out!

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.